Abstracts tagged "rheumatic disease and risk"

Abstract Number: 587 • 2015 ACR/ARHP Annual Meeting
Defining the Conditions Under Which Long-Term Glucocorticoid Treatment Has a Good Benefit-Risk Ratio
Cindy Strehl¹, Johannes W J Bijlsma², Maarten de Wit³, Maurizio Cutolo⁴, Raphaele Seror⁵, Kevin L. Winthrop⁶, Frank Buttgereit¹ and EULAR Task Force on Glucocorticoids, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Medical Humanities, VU Medical Centre, Amsterdam, Netherlands, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁵Department of Rheumatology, Assistance Publique–Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France, ⁶Division of Infectious Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Glucocorticoids (GC) are used to treat a wide range of inflammatory diseases including rheumatic and musculoskeletal diseases. EULAR recommendations on GC therapy are up…
Abstract Number: 1370 • 2013 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases
Wieneke van den Hombergh¹, Annelies van Ede², J. Fransen³, Femke BG lamers-Karnebeek³, Saskia Kuipers⁴ and Matthijs Janssen⁵, ¹Rheumatology, UMC st. Radboud, Nijmegen, Netherlands, ²Rheumatology, UMC st Radboud, Nijmegen, Netherlands, ³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Microbiology, UMC st Radboud, Nijmegen, Netherlands, ⁵Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands
Background/Purpose: Pneumocystis jirovecii is a fungal pathogen that causes pneumonia in immunocompromized hosts. Prednisone is frequently suggested as a risk factor for developing pneumocystis pneumonia (PCP) in patients with rheumatic diseases. If prednisone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].